The VEGF Antibody (CAB0280) is a high-quality antibody developed for reliable detection and analysis of target proteins. This antibody, produced in rabbits, has high reactivity with human samples and has been validated for use in Western blot applications. By binding to the VEGFA protein, it allows for accurate detection and analysis in different cell types, making it suitable for studies in cancer biology, cardiovascular diseases, and other fields related to vascular biology.
This antibody is validated for use in WB, IHC-P, IF/ICC, ELISA applications and has demonstrated reactivity against Human, Mouse, Rat samples.
Product Name:
VEGF Antibody
SKU:
CAB0280
Size:
20μL, 100μL
Reactivity:
Human, Mouse, Rat
Conjugate:
Unconjugated
Immunogen:
Synthetic peptide. This information is considered to be commercially sensitive.
Recommended starting concentration is 1 μg/mL. Please optimize the concentration based on your specific assay requirements.
Synonyms:
VPF, VEGF, MVCD1, VEGFA
Positive Sample:
U-87MG, K-562, Mouse heart, Rat heart
Cellular Localization:
Secreted.
Calculated MW:
27kDa
Observed MW:
39kDa/43kDa
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines.
Purification Method
Affinity purification
Gene ID
7422
RRID
AB_2757092
Buffer Information
Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS containing 50% glycerol, preserved with proclin300 or sodium azide, pH 7.3.
Western blot analysis of various lysates, using VEGFA Rabbit pAb (CAB0280) at 1:1000 dilution. Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution. Lysates/proteins: 25μg per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Enhanced Kit (AbGn00021). Exposure time: 30s.
Immunohistochemistry analysis of paraffin-embedded Human lung cancer using VEGFA Rabbit pAb (CAB0280) at dilution of 1:200 (40x lens). High pressure antigen retrieval performed with 0.01M Citrate buffer (pH 6.0) prior to IHC staining.
